{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087259","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.015926+00:00","generated_at":"2026-05-31T10:46:33.556272+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Iovance posts Q2 product revenue $31.1M; guides FY24 $160-165M, FY25 $450-475M","bullets":["Q2 net loss $97.1M ($0.34/shr) vs. $106.5M ($0.47) a year ago; revenue $31.1M from Amtagvi ($12.8M) and Proleukin ($18.3M).","FY24 product revenue guidance $160-165M; FY25 $450-475M; Q3 2024 expected $53-55M.","Over 55 patients infused with Amtagvi since April; >50 ATCs in 29 states; >70 ATCs targeted by year-end.","Cash $449.6M as of July 24, up from $346.3M at Dec 2023, partly from ~$200M ATM equity raise.","Lifileucel pipeline: frontline melanoma TILVANCE-301 enrolling globally; NSCLC Phase 2 accelerating; endometrial cancer Phase 2 started."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087259","json":"https://secwatch.observer/filing/0001104659-24-087259.json","markdown":"https://secwatch.observer/filing/0001104659-24-087259.md","text":"https://secwatch.observer/filing/0001104659-24-087259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924087259/0001104659-24-087259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924087259/tm2421110d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:46:33.556272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}